Soleus Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Soleus Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.7M	Buy	1,449,915 +539,915	+59%	+$15.6M	1.85%	14
2025 Q4	$22.6M	Buy	+910,000	New	+$18.3M	0.83%	37
2025 Q3	–	Sell	-76,493	Closed	-$1M	–	97
2025 Q2	$1M	Buy	76,493 +4,193	+6%	+$60.5K	0.07%	83
2025 Q1	$1.59M	Sell	72,300 -111,000	-61%	-$2.91M	0.11%	65
2024 Q4	$4.89M	Buy	+183,300	New	+$5.84M	0.31%	54
2021 Q4	–	Sell	-31,300	Closed	-$520K	–	79
2021 Q3	$520K	Hold	31,300	–	–	0.08%	72
2021 Q2	$668K	Sell	31,300 -68,700	-69%	-$1.88M	0.1%	62
2021 Q1	$3.25M	Buy	+100,000	New	+$3.24M	0.59%	37

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return